The partnership will employ the ALS-Digital Twin Generator of Unlearn to enhance the trial's evaluation process.
ProJenX and Unlearn partnered to implement genAI technology for a Phase I trial of prosetin for amyotrophic lateral sclerosis ...
11h
The gross proceeds from the offering are expected to be approximately $5 million, prior to deducting placement agent’s fees and other offering expenses payable by the Company. Pasithea intends to use ...
Sudden uncontrollable and inappropriate laughing or crying is a symptom of pseudobulbar affect (PBA), a neurological ...
In a first-of-a-kind collaboration, Target ALS, a foundation breaking down barriers to amyotrophic lateral sclerosis (ALS) ...
A tailored cocktail of genes can reprogram a subset of progenitors to no longer produce glial cells and instead develop into neurons involved in motor control.
A New Bedford man, Joseph Smith, admitted to stealing over $450,000 in disability benefits from a veteran with ALS and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback